Arns, Beatriz http://orcid.org/0000-0002-4464-9763
Horvath, Jaqueline Driemeyer C. http://orcid.org/0000-0001-8440-6590
Rech, Gabriela Soares http://orcid.org/0000-0001-5122-8820
Sesin, Guilhermo Prates http://orcid.org/0000-0002-8607-3467
Agani, Crepin Aziz Jose Oluwafoumi http://orcid.org/0000-0001-5987-1351
da Rosa, Bruna Silveira http://orcid.org/0009-0008-7547-1815
dos Santos, Tiago Marcon http://orcid.org/0000-0002-7328-6092
Brochier, Liliane Spencer Bittencourt http://orcid.org/0000-0003-0778-5018
Cavalcanti, Alexandre Biasi http://orcid.org/0000-0003-2798-6263
Tomazini, Bruno Martins http://orcid.org/0000-0001-6763-6132
Pereira, Adriano Jose http://orcid.org/0000-0002-3528-3800
Veiga, Viviane Cordeiro http://orcid.org/0000-0002-0287-3601
Nascimento, Giovana Marssola http://orcid.org/0009-0005-5071-3775
Kalil, Andre C. http://orcid.org/0000-0002-6489-6294
Zavascki, Alexandre P. http://orcid.org/0000-0001-5331-4837
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol
https://doi.org/10.1007/s40121-023-00897-9
Funding for this research was provided by:
Support Program for Institutional Development of the Unified Health System
Article History
Received: 30 October 2023
Accepted: 23 November 2023
First Online: 16 December 2023
Declarations
:
: All authors confirm that they have no conflicts of interest to declare. Alexandre P. Zavascki is a research fellow of the National Council for Scientific and Technological Development (CNPq), Ministry of Science and Technology, Brazil.
: This study has been conducted in accordance with the Brazilian and international regulations set forth in the following documents: Declaration of Helsinki; Brazilian National Health Council Resolution CNS 466/2012 and related Brazilian Ministry of Health publications; and 1996 ICH Harmonized Tripartite Guideline for Good Clinical Practice. The study protocol and amendments have been approved by the research ethics committee (IRB) of the coordinating center (Hospital Moinhos de Vento), as well as IRBs from all other participant sites.